Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.50 +1.6%	$2.19	$0.90 ▼ $2.96	$90.48M	0.99	109,022 shs	19,195 shs
CAPR Capricor Therapeutics	$8.30 +3.2%	$9.48	$3.79 ▼ $23.40	$379.14M	0.59	2.03 million shs	1.28 million shs
FULC Fulcrum Therapeutics	$6.85 +4.7%	$7.16	$2.32 ▼ $10.13	$370.52M	2.47	589,113 shs	307,424 shs
NWBO Northwest Biotherapeutics	$0.24 +5.1%	$0.25	$0.17 ▼ $0.48	$349.08M	-1.14	3.32 million shs	2.99 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	+4.24%	-4.28%	+10.81%	+78.26%	-32.79%
CAPR Capricor Therapeutics	+2.81%	+4.82%	+5.24%	+4.82%	+105.10%
FULC Fulcrum Therapeutics	+3.15%	-4.94%	-16.48%	+16.16%	-27.41%
NWBO Northwest Biotherapeutics	-7.15%	-8.47%	-1.19%	-20.57%	-25.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	2.363 of 5 stars	3.5	5.0	0.6	1.7	0.0
CAPR Capricor Therapeutics	3.6651 of 5 stars	4.6	4.0	2.8	0.8	0.6
FULC Fulcrum Therapeutics	1.9531 of 5 stars	3.3	3.0	1.8	1.7	0.0
NWBO Northwest Biotherapeutics	0.328 of 5 stars	0.0	2.0	4.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$9.00	260.00% Upside
CAPR Capricor Therapeutics	3.11	Buy	$22.56	171.75% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	10.53% Upside
NWBO Northwest Biotherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARMP, NWBO, FULC, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
7/11/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$77.00 ➝ $24.00
6/30/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/26/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
6/25/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	CAPR Capricor Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00
6/24/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$5.17M	17.50	N/A	N/A	($1.33) per share	-1.88
CAPR Capricor Therapeutics	$22.27M	17.02	N/A	N/A	$3.20 per share	2.59
FULC Fulcrum Therapeutics	$80M	4.63	N/A	N/A	$3.96 per share	1.73
NWBO Northwest Biotherapeutics	$1.38M	252.96	N/A	N/A	($0.07) per share	-3.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$18.92M	-$1.64	N/A	N/A	N/A	N/A	N/A	-25.06%	N/A
CAPR Capricor Therapeutics	-$40.47M	-$1.64	N/A	N/A	N/A	-181.71%	-61.50%	-50.32%	8/13/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A
NWBO Northwest Biotherapeutics	-$83.78M	-$0.07	N/A	∞	N/A	-5,757.57%	N/A	-303.49%	8/14/2025 (Estimated)

Latest ARMP, NWBO, FULC, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$2.60 million	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
5/15/2025	Q1 2025	NWBO Northwest Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	$0.38 million
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	0.12	0.12
CAPR Capricor Therapeutics	N/A	6.55	6.55
FULC Fulcrum Therapeutics	N/A	24.42	24.42
NWBO Northwest Biotherapeutics	N/A	0.06	0.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
CAPR Capricor Therapeutics	21.68%
FULC Fulcrum Therapeutics	89.83%
NWBO Northwest Biotherapeutics	0.04%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	84.50%
CAPR Capricor Therapeutics	10.50%
FULC Fulcrum Therapeutics	7.00%
NWBO Northwest Biotherapeutics	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	70	36.19 million	5.61 million	Not Optionable
CAPR Capricor Therapeutics	101	45.68 million	40.88 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
NWBO Northwest Biotherapeutics	20	1.48 billion	1.35 billion	Not Optionable

ARMP, NWBO, FULC, and CAPR Headlines

Recent News About These Companies

Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?

August 7, 2025 | marketbeat.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened

July 29, 2025 | marketbeat.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below 200 Day Moving Average - Here's What Happened

July 19, 2025 | marketbeat.com

NWBO - Northwest Biotherapeutics Inc News - Morningstar

July 11, 2025 | morningstar.comM

Northwest Biotherapeutics, Inc. (NWBO) - Yahoo Finance

June 29, 2025 | uk.finance.yahoo.com

NWBO Northwest Biotherapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

June 13, 2025 | finanznachrichten.de

Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

June 11, 2025 | prnewswire.com

Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval

April 22, 2025 | seekingalpha.com

Citadel Securities, Virtu Must Face Biotech Stock Spoof Suit (1)

March 29, 2025 | news.bloomberglaw.comN

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

January 13, 2025 | msn.com

Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing

December 26, 2024 | prnewswire.com

Northwest Biotherapeutics: All Is Not Well With This One

December 14, 2024 | seekingalpha.com

Behind the Bell: Arcutis Biotherapeutics

November 5, 2024 | nasdaq.com

Northwest Registered Agent Review 2024: Features, Pricing & More

October 24, 2024 | forbes.com

0K95.IL,0P0000AFQ5,0 (0K95.IL)

September 14, 2024 | nz.finance.yahoo.com

Traders News Digs into the Biotech Space and Releases New Feature Profile

August 15, 2024 | br.advfn.com

Northwest Biotherapeutics addresses rumors and market activity

August 4, 2024 | uk.investing.com

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

July 3, 2024 | prnewswire.com

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

June 17, 2024 | prnewswire.com

Northwest Biotherapeutics Inc (NWBO) Dividend History

May 25, 2024 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARMP, NWBO, FULC, and CAPR Company Descriptions

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$2.50 +0.04 (+1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.00 (+0.20%)

As of 04:10 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Capricor Therapeutics NASDAQ:CAPR

$8.30 +0.26 (+3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$8.30 -0.01 (-0.06%)

As of 04:17 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Fulcrum Therapeutics NASDAQ:FULC

$6.85 +0.31 (+4.74%)

Closing price 04:00 PM Eastern

Extended Trading

$6.84 -0.01 (-0.15%)

As of 04:10 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Northwest Biotherapeutics OTCMKTS:NWBO

$0.24 +0.01 (+5.13%)

As of 03:59 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time